Changelog — 2026-02-10
2026-02-10
A
AUPH
Aurinia Pharmaceuticals Inc.
Status: RECRUITING → TERMINATED (DSMB recommendation) — PHASE3
NCT05288855
• Phase 3 • Status: Recruiting → Terminated • Why stopped: DSMB recommendation
🚩 MAJOR
2026-02-10
U
UTHR
UNITED THERAPEUTICS Corp
Status: ACTIVE_NOT_RECRUITING → COMPLETED — PHASE3
NCT04708782
• Phase 3 • Status: Active, not recruiting → Completed
MEDIUM
2026-02-10
P
PTCT
PTC THERAPEUTICS, INC.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT05166161
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-10
A
ARVN
ARVINAS, INC.
Enrollment 112→255 (128%) — PHASE1
NCT06393738
• Phase 1 • Enrollment 112→255 (+128%)
MEDIUM
2026-02-10
ABBV
AbbVie Inc.
Enrollment 258→268 (4%) — PHASE2
NCT07145918
• Phase 2 • Enrollment 258→268 (+4%)
MEDIUM
2026-02-10
ABBV
AbbVie Inc.
Primary endpoint added: Number of Participants Experiencing Adverse Events — PHASE3
NCT05711394
• Phase 3
MEDIUM
2026-02-10
O
ONON
On Holding AG
Enrollment 378→196 (-48%) — NA
NCT05736666
• Na • Enrollment 378→196 (-48%)
MEDIUM
2026-02-10
C
CL
COLGATE PALMOLIVE CO
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT06365047
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-10
U
UTHR
UNITED THERAPEUTICS Corp
Enrollment 576→598 (4%) — PHASE3
NCT04708782
• Phase 3 • Enrollment 576→598 (+4%)
MEDIUM
2026-02-10
R
RVMD
Revolution Medicines, Inc.
Locations updated — PHASE1
NCT06162221
• Phase 1
MEDIUM
2026-02-10
A
AUPH
Aurinia Pharmaceuticals Inc.
Enrollment 40→9 (-78%) — PHASE3
NCT05288855
• Phase 3 • Enrollment 40→9 (-78%)
MEDIUM
2026-02-10
A
AUPH
Aurinia Pharmaceuticals Inc.
Locations updated — PHASE3
NCT05288855
• Phase 3
MEDIUM
2026-02-10
REGN
REGENERON PHARMACEUTICALS, INC.
Enrollment 150→151 (1%) — PHASE2
NCT06190951
• Phase 2 • Enrollment 150→151 (+1%)
MEDIUM
2026-02-10
M
MRBK
Meridian Corp
Study arms updated — PHASE2 — investigator-sponsored (collaborator: MRBK)
NCT03954236
• Phase 2
MEDIUM
2026-02-10
C
CLDX
Celldex Therapeutics, Inc.
Enrollment 120→131 (9%) — PHASE2
NCT06727552
• Phase 2 • Enrollment 120→131 (+9%)
MEDIUM
2026-02-10
A
ALC
ALCON INC
Primary endpoint added: Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 1 — PHASE3
NCT06544707
• Phase 3
MEDIUM
2026-02-10
MRK
Merck & Co., Inc.
Study arms updated — NA — investigator-sponsored (collaborator: MRK)
NCT07217262
• Na
MEDIUM
2026-02-10
N
NRC
NATIONAL RESEARCH CORP
Enrollment 224→178 (-21%) — NA
NCT05017779
• Na • Enrollment 224→178 (-21%)
MEDIUM
2026-02-10
R
RVMD
Revolution Medicines, Inc.
Enrollment 210→534 (154%) — PHASE1
NCT06128551
• Phase 1 • Enrollment 210→534 (+154%)
MEDIUM
2026-02-10
R
RVMD
Revolution Medicines, Inc.
Primary endpoint added: Changes in vital signs in Phase 1b — PHASE1
NCT06128551
• Phase 1
MEDIUM
2026-02-10
R
RVMD
Revolution Medicines, Inc.
Locations updated — PHASE1
NCT06128551
• Phase 1
MEDIUM
2026-02-10
C
CHCO
CITY HOLDING CO
Enrollment 190→176 (-7%)
NCT07100158
• Enrollment 190→176 (-7%)
MEDIUM